Claims for Patent: 7,772,208
✉ Email this page to a colleague
Summary for Patent: 7,772,208
Title: | 2\',3\'-dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
Abstract: | A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a .beta.-L- or .beta.-D-2\',3\'-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient. |
Inventor(s): | Schinazi; Raymond (Atlanta, GA), Striker; Robert (Madison, WI), Shi; Junxing (Duluth, GA) |
Assignee: | Pharmasset, Inc. (Princeton, NJ) Leland Stanford Junior University (Palo Alto, CA) Emory University (Atlanta, GA) |
Application Number: | 11/970,908 |
Patent Claims: | 1. A pharmaceutical composition for the treatment of an HCV infection in a host, comprising an effective treatment amount of a 2',3'-dideoxynucleoside of the formula: ##STR00009## or
a pharmaceutically acceptable salt thereof, wherein (i) X is S.dbd.O, SO.sub.2, NR.sup.1, N.sup.+R.sup.1R.sup.2, CHF or CR.sup.3R.sup.4; R.sup.1 and R.sup.2 are independently C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, or C.sub.3-8 cycloalkyl; R.sup.3 and
R.sup.4 are independently hydrogen, halogen (F, Cl, Br, or I), OH or OR.sup.5, with the proviso that R.sup.3 and R.sup.4 are not both hydrogen; R.sup.5 is hydrogen, an alkyl, an acyl, or a silyl; (ii) Y is NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7, OH or
OR.sup.8 each R.sup.6, R.sup.7 and R.sup.7 is independently H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-8 cycloalkyl, cyclopropyl, or C.sub.2-6 acyl; (iii) Z is chosen from hydrogen, halogen (F, Cl, Br, or I), C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, CN, CF.sub.3, N.sub.3, NO.sub.2, aryl, heteroaryl and COR.sup.9; R.sup.9 is chosen from H, OH, SH, C.sub.1-6 alkyl, C.sub.1-6 aminoalkyl, C.sub.1-6 alkoxy and C.sub.1-6 thioalkyl; and (iv) R is phosphate; acyl;
--C(O)R.sup.10, alkyl; sulfonate ester; sulfonyl; a lipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group; R.sup.10 is a C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, aryl,
monophosphate, diphosphate, triphosphate, or --P(O)(OR.sup.11).sub.2; each R.sup.11 is independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or a hydroxyl-protecting group; together with pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein Z is not hydrogen. 3. The pharmaceutical composition of claim 1, wherein Z is a halogen (F, Cl, Br, or I). 4. The pharmaceutical composition of claim 3, wherein Z is F. 5. The pharmaceutical composition of claim 1, wherein the 2',3'-dideoxynucleoside is in the .beta.-L-configuration. 6. The pharmaceutical composition of claim 5, wherein the .beta.-L-2',3'-dideoxynucleoside is enantiomerically enriched. 7. The pharmaceutical composition of claim 5, wherein the .beta.-L-2',3'-dideoxynucleoside is substantially free of the .beta.-D-2',3'-dideoxynucleoside. 8. The pharmaceutical composition of claim 5, wherein the .beta.-L-2',3'-dideoxynucleoside is in isolated form. 9. A pharmaceutical composition for the treatment of an HCV infection in a host, comprising an effective amount of a compound of the formula: ##STR00010## or a pharmaceutically acceptable salt, wherein Z' is CF.sub.3 or N.sub.3; together with a pharmaceutically acceptable carrier. 10. A pharmaceutical composition for the treatment of an HCV infection in a host, comprising an effective amount of a compound of the formula: ##STR00011## or a pharmaceutically acceptable salt thereof, wherein (i) R.sup.6 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-8 cycloalkyl, cyclopropyl, or C.sub.2-6 acyl; and (ii) R is hydrogen, phosphate, acyl, --C(O)R.sup.10, alkyl, sulfonate ester, sulfonyl, a lipid, an amino acid, a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group; (iii) Z' is CF.sub.3 or N.sub.3; together with a pharmaceutically acceptable carrier. 11. The pharmaceutical composition of claim 10, wherein the .beta.-L-2',3'-dideoxynucleoside is enantiomerically enriched. 12. The pharmaceutical composition of claim 10, wherein the .beta.-L-2',3'-dideoxynucleoside is substantially free of the .beta.-D-2',3'-dideoxynucleoside. 13. The pharmaceutical composition of claim 10, wherein the .beta.-L-2',3'-dideoxynucleoside is in an isolated form. 14. A pharmaceutical composition for reducing the biological activity of a Flaviviridae viral infection in a host comprising an effective amount of a 2',3'-dideoxynucleoside of the formula: ##STR00012## or a pharmaceutically acceptable salt thereof, wherein (i) X is S.dbd.O, SO.sub.2, NR.sup.1, N.sup.+R.sup.1R.sup.2, CHF or CR.sup.3R.sup.4; R.sup.1 and R.sup.2 are independently C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, or C.sub.3-8 cycloalkyl; R.sup.3 and R.sup.4 are independently hydrogen, halogen (F, Cl, Br, or I), OH or OR.sup.5, with the proviso that R.sup.3 and R.sup.4 are not both hydrogen; R.sup.5 is hydrogen, an alkyl, an acyl, or a silyl; (ii) Y is NH.sub.2, NHR.sup.6, NR.sup.6R.sup.7, OH or OR.sup.8 each R.sup.6, R.sup.7 and R.sup.7 is independently H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-8 cycloalkyl, cyclopropyl, or C.sub.2-6 acyl; (iii) Z is chosen from hydrogen, halogen (F, Cl, Br, or I), C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, CN, CF.sub.3, N.sub.3, NO.sub.2, aryl, heteroaryl and COR.sup.9; R.sup.9 is chosen from H, OH, SH, C.sub.1-6 alkyl, C.sub.1-6 aminoalkyl, C.sub.1-6 alkoxy and C.sub.1-6 thioalkyl; and (iv) R is phosphate; acyl; --C(O)R.sup.10, alkyl; sulfonate ester; sulfonyl; a lipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group; R.sup.10 is a C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, aryl, monophosphate, diphosphate, triphosphate, or --P(O)(OR.sup.11).sub.2; each R.sup.11 is independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or a hydroxyl-protecting group; together with a pharmaceutically acceptable carrier. 15. The pharmaceutical composition of claim 14, wherein Z is not hydrogen. 16. The pharmaceutical composition of claim 14, wherein Z is a halogen (F, Cl, Br, or I). 17. The pharmaceutical composition of claim 16, wherein Z is F. 18. The pharmaceutical composition of claim 14, wherein the 2',3'-dideoxynucleoside is in the .beta.-L-configuration. 19. A pharmaceutical composition for reducing the biological activity of a Flaviviridae viral infection in a host comprising an effective amount of a compound of the formula: ##STR00013## or a pharmaceutically acceptable salt thereof, wherein Z' is CF.sub.3 or N.sub.3; together with a pharmaceutically acceptable carrier. 20. A pharmaceutical composition for reducing the biological activity of a Flaviviridae viral infection in a host comprising an effective amount of a compound of the formula: ##STR00014## or a pharmaceutically acceptable salt thereof, wherein (i) R.sup.6 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-8 cycloalkyl, cyclopropyl, or C.sub.2-6 acyl; and (ii) R is phosphate; acyl; --C(O)R.sup.10, alkyl; sulfonate ester; sulfonyl; a lipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group; (iii) Z' is CF.sub.3 or N.sub.3; together with a pharmaceutically acceptable carrier. 21. The pharmaceutical composition according to claim 14, wherein the Flaviviridae viral infection is an HCV infection. 22. The pharmaceutical composition according to claim 1, further comprising one or more other antiviral agent(s). 23. The pharmaceutical composition according to claim 22, wherein the antiviral agent is selected from the group consisting of ribavirin, interferon, PEGASYS (pegylated interferon alfa-2a), INFERGEN (interferon alfacon-1), OMNIFERON (natural interferon), ALBUFERON, REBIF (interferon beta-1a), Omega Interferon, Oral Interferon Alpha, Interferon gamma-1b, Interleukin-10, IP-501, Merimebodib VX-497, AMANTADINE (Symmetrel), HEPTAZYME, IDN-6556, XTL-002, HCV/MF59, CIVACIR, LEVOVIRIN, VIRAMIDINE, ZADAXIN (thymosin alfa-1), CEPLENE (histamine dihydrochloride), VX 950/LY 570310, ISIS 14803, IDN-6556 and JTK 003. 24. The pharmaceutical composition according to claim 1, wherein the host is a human. 25. The pharmaceutical composition according to claim 14, wherein the host is also infected with HIV and/or HBV. 26. The pharmaceutical composition according to claim 25, wherein the host is a human. |
Details for Patent 7,772,208
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2022-08-01 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2022-08-01 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2022-08-01 |
Kadmon Pharmaceuticals Llc | INFERGEN | interferon alfacon-1 | Injection | 103663 | 10/06/1997 | ⤷ Try a Trial | 2022-08-01 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Try a Trial | 2022-08-01 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Try a Trial | 2022-08-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.